Page last updated: 2024-11-05

tranexamic acid and Angioblastic Meningioma

tranexamic acid has been researched along with Angioblastic Meningioma in 6 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Research Excerpts

ExcerptRelevanceReference
"Based upon Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), the authors collected fully published English literature on the administration of tranexamic acid for patients undergoing intracranial meningioma surgery using the keywords ["tranexamic acid" and "meningioma"] and its synonyms from Cochrane Central Database, the WHO International Clinical Trials Registry Platform (ICTRP), ClinicalTrials."9.41A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma. ( Chadid, DP; July, J; Quintero-Consuegra, M; Wijaya, JH, 2023)
"Tranexamic acid (TXA) is an antifibrinolytic that is widely used to reduce surgical bleeding."7.83Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial. ( Li, S; Liu, M; Peng, Y; Sessler, DI; Wu, Y; Yan, X; Yang, J; Zeng, M; Zhang, L; Zhou, D, 2024)
"Tranexamic acid (TXA) has been proven to prevent thrombolysis and reduce bleeding and blood transfusion requirements in various surgical settings."7.30The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial. ( Jin, H; Li, M; Li, S; Liu, M; Liu, X; Ma, T; Peng, Y; Wang, J; Wu, Y; Yang, J; Yu, H; Zeng, M; Zhang, L; Zhang, X, 2023)
" However, postoperative seizure, as one of the major adverse effects of TXA infusion, has been a concern that restricts its utility in neurosurgery."7.11Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial. ( Dong, J; Li, R; Li, S; Liu, X; Ma, T; Peng, Y; Wang, J; Yan, X; Zeng, M; Zhang, X, 2022)
"Tranexamic Acid (TXA) has been used in medical and surgical practice to reduce haemorrhage."7.01Tranexamic acid use in meningioma surgery - A systematic review and meta-analysis. ( Bakhsh, A; Brodbelt, AR; Clynch, AL; Gillespie, CS; Islim, AI; Jenkinson, MD; Keshwara, SM; Kumar, S; Mills, SJ; Millward, CP; Mustafa, MA; Richardson, GE; Zakaria, R, 2023)
"Based upon Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), the authors collected fully published English literature on the administration of tranexamic acid for patients undergoing intracranial meningioma surgery using the keywords ["tranexamic acid" and "meningioma"] and its synonyms from Cochrane Central Database, the WHO International Clinical Trials Registry Platform (ICTRP), ClinicalTrials."5.41A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma. ( Chadid, DP; July, J; Quintero-Consuegra, M; Wijaya, JH, 2023)
"Tranexamic acid (TXA) is an antifibrinolytic that is widely used to reduce surgical bleeding."3.83Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial. ( Li, S; Liu, M; Peng, Y; Sessler, DI; Wu, Y; Yan, X; Yang, J; Zeng, M; Zhang, L; Zhou, D, 2024)
"Tranexamic acid (TXA) has been proven to prevent thrombolysis and reduce bleeding and blood transfusion requirements in various surgical settings."3.30The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial. ( Jin, H; Li, M; Li, S; Liu, M; Liu, X; Ma, T; Peng, Y; Wang, J; Wu, Y; Yang, J; Yu, H; Zeng, M; Zhang, L; Zhang, X, 2023)
" However, postoperative seizure, as one of the major adverse effects of TXA infusion, has been a concern that restricts its utility in neurosurgery."3.11Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial. ( Dong, J; Li, R; Li, S; Liu, X; Ma, T; Peng, Y; Wang, J; Yan, X; Zeng, M; Zhang, X, 2022)
"Tranexamic Acid (TXA) has been used in medical and surgical practice to reduce haemorrhage."3.01Tranexamic acid use in meningioma surgery - A systematic review and meta-analysis. ( Bakhsh, A; Brodbelt, AR; Clynch, AL; Gillespie, CS; Islim, AI; Jenkinson, MD; Keshwara, SM; Kumar, S; Mills, SJ; Millward, CP; Mustafa, MA; Richardson, GE; Zakaria, R, 2023)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (16.67)24.3611
2020's5 (83.33)2.80

Authors

AuthorsStudies
Li, S3
Yan, X2
Li, R1
Zhang, X2
Ma, T2
Zeng, M3
Dong, J1
Wang, J3
Liu, X2
Peng, Y3
Wijaya, JH1
July, J1
Quintero-Consuegra, M1
Chadid, DP1
Clynch, AL1
Gillespie, CS1
Richardson, GE1
Mustafa, MA1
Islim, AI1
Keshwara, SM1
Bakhsh, A1
Kumar, S1
Zakaria, R1
Millward, CP1
Mills, SJ1
Brodbelt, AR1
Jenkinson, MD1
Yu, H1
Liu, M2
Yang, J2
Wu, Y2
Li, M1
Zhang, L2
Jin, H1
Zhou, D1
Sessler, DI1
Hooda, B1
Chouhan, RS1
Rath, GP1
Bithal, PK1
Suri, A1
Lamsal, R1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Parallel-group, Placebo Control, Non-inferiority Trial to Investigate the Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection[NCT04595786]600 participants (Actual)Interventional2020-10-30Active, not recruiting
The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal[NCT03558516]Phase 380 participants (Actual)Interventional2018-08-01Completed
Efficacy of Tranexamic Acid (TXA) in Humerus ORIF[NCT05802238]Phase 2130 participants (Anticipated)Interventional2023-04-12Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cis-atracurium Requirement

Amount of cis-atracurium usage during surgery (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.

Interventionmg/kg/hr (Mean)
Group NSS0.08
Group Mg0.08

Fentanyl Requirement

Amount of fentanyl usage during surgery (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.

Interventionmcg/kg/hr (Mean)
Group NSS0.65
Group Mg0.6

Intraoperative Blood Loss

We measure the amount of blood loss in the operative room in suction box, gauze and plastic bag. The unit measure is millimeter. (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.

Interventionml (Median)
Group NSS510
Group Mg500

Intraoperative Packed Red Cell (PRC) Transfusion

The amount of blood transfusion in patient who required PRC transfusion intraoperatively. (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.

Interventionunit of packed red cell (Median)
Group NSS2
Group Mg1

Patient Received Intraoperative Packed Red Cell (PRC)

Number of patients who required Intraoperative PRC transfusion (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.

InterventionParticipants (Count of Participants)
Group NSS10
Group Mg7

Postoperative MOCA Score

"MOCA or Montreal Cognitive Assessment is a screening instrument used to facilitate the assessment of cognitive impairment.~MOCA scores range between 0-30, do higher values represent a better outcome. A score of 26 or over is considered to be normal. We measure Montreal assessment score for assess cognitive function after operation at postoperative day 3-7." (NCT03558516)
Timeframe: Postoperative day 3-7

Interventionscore on the MOCA scale (Median)
Group NSS23
Group Mg25

Sevoflurane Requirement

Amount of sevoflurane agents usage during surgery. The unit of measurement of volatile agent is minimum alveolar concentration (MAC). 1 MAC-hour was defined as 2% of sevoflurane for 1 hour duration. (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.

Interventionaverage minimum alveolar concentration (Mean)
Group NSS0.65
Group Mg0.66

Reviews

2 reviews available for tranexamic acid and Angioblastic Meningioma

ArticleYear
A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma.
    Journal of neuro-oncology, 2023, Volume: 161, Issue:2

    Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Meningeal Neoplasms; Meningioma; Middl

2023
Tranexamic acid use in meningioma surgery - A systematic review and meta-analysis.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2023, Volume: 110

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Meningeal Neoplasms; Meningioma; Tranexamic A

2023

Trials

4 trials available for tranexamic acid and Angioblastic Meningioma

ArticleYear
Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial.
    BMJ open, 2022, Feb-02, Volume: 12, Issue:2

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Meningeal Neoplasms; Men

2022
The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial.
    PloS one, 2023, Volume: 18, Issue:8

    Topics: Blood Loss, Surgical; Brain; Humans; Meningeal Neoplasms; Meningioma; Randomized Controlled Trials a

2023
Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial.
    Journal of clinical anesthesia, 2024, Volume: 92

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Meningeal Neoplasms; Men

2024
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2017, Volume: 41

    Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica

2017
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2017, Volume: 41

    Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica

2017
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2017, Volume: 41

    Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica

2017
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2017, Volume: 41

    Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica

2017